Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

The role of therapy in impairing quality of life in dermatological patients : A multinational study

Balieva, Flora N. ; Finlay, Andrew Y. ; Kupfer, Jörg ; Tomas Aragones, Lucia ; Lien, Lars ; Gieler, Uwe ; Poot, Francoise ; Jemec, Gregor B.E. ; Misery, Laurent and Kemeny, Lajos , et al. (2018) In Acta Dermato-Venereologica 98(6). p.563-569
Abstract

Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/ drug reactions (10.2%), psoriasis (9.9%),... (More)

Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/ drug reactions (10.2%), psoriasis (9.9%), vasculi-tis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Burden of skin disease, Dermatological therapy, DLQI, HRQoL, Quality of life, Therapy burden
in
Acta Dermato-Venereologica
volume
98
issue
6
pages
7 pages
publisher
Medical Journals Limited
external identifiers
  • scopus:85048506517
  • pmid:29507999
ISSN
0001-5555
DOI
10.2340/00015555-2918
language
English
LU publication?
no
id
0a2d717b-bf2f-4a1d-8b71-49df964f0dfb
date added to LUP
2018-07-02 09:15:22
date last changed
2024-06-11 17:20:06
@article{0a2d717b-bf2f-4a1d-8b71-49df964f0dfb,
  abstract     = {{<p>Skin disease and its therapy affect health-related quality of life (HRQoL). The aim of this study was to measure the burden caused by dermatological therapy in 3,846 patients from 13 European countries. Adult outpatients completed questionnaires, including the Dermatology Life Quality Index (DLQI), which has a therapy impact question. Therapy issues were reported by a majority of patients with atopic dermatitis (63.4%), psoriasis (60.7%), prurigo (54.4%), hidradenitis suppurativa (54.3%) and blistering conditions (53%). The largest reduction in HRQoL attributable to therapy, as a percentage of total DLQI, adjusted for confounders, was seen in blistering conditions (10.7%), allergic/ drug reactions (10.2%), psoriasis (9.9%), vasculi-tis/immunological ulcers (8.8%), atopic dermatitis (8.7%), and venous leg ulcers (8.5%). In skin cancer, although it had less impact on HRQoL, the reduction due to therapy was 6.8%. Treatment for skin disease contributes considerably to reducing HRQoL: the burden of dermatological treatment should be considered when planning therapy and designing new dermatological therapies.</p>}},
  author       = {{Balieva, Flora N. and Finlay, Andrew Y. and Kupfer, Jörg and Tomas Aragones, Lucia and Lien, Lars and Gieler, Uwe and Poot, Francoise and Jemec, Gregor B.E. and Misery, Laurent and Kemeny, Lajos and Sampogna, Francesca and Van Middendorp, Henriët and Halvorsen, Jon Anders and Ternowitz, Thomas and Szepietowski, Jacek C. and Potekaev, Nikolay and Marron, Servando E. and Altunay, Ilknur K. and Salek, Sam S. and Dalgard, Florence J.}},
  issn         = {{0001-5555}},
  keywords     = {{Burden of skin disease; Dermatological therapy; DLQI; HRQoL; Quality of life; Therapy burden}},
  language     = {{eng}},
  month        = {{06}},
  number       = {{6}},
  pages        = {{563--569}},
  publisher    = {{Medical Journals Limited}},
  series       = {{Acta Dermato-Venereologica}},
  title        = {{The role of therapy in impairing quality of life in dermatological patients : A multinational study}},
  url          = {{http://dx.doi.org/10.2340/00015555-2918}},
  doi          = {{10.2340/00015555-2918}},
  volume       = {{98}},
  year         = {{2018}},
}